BCAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bioatla Inc (BCAB) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown a significant price increase recently, the lack of positive financial performance, hedge fund selling, and absence of strong trading signals or positive catalysts make it unsuitable for a long-term investment strategy.
The MACD is positive and expanding, indicating upward momentum. RSI is at 75.81, which is approaching overbought levels but still neutral. Moving averages are converging, suggesting no clear trend. Resistance levels at 0.223 and 0.249 have been breached, but the stock remains volatile.
NULL identified. No recent news or significant insider activity.
Hedge funds are selling the stock with a 760.39% increase in selling activity over the last quarter. Financial performance is weak, with revenue dropping to zero and gross margin declining by 100%.
In Q3 2025, revenue dropped to $0 (-100% YoY). Net income improved to -$15.78M (+49.05% YoY), and EPS increased to -0.27 (+22.73% YoY). Gross margin also dropped to 0 (-100% YoY), indicating no profitability.
No data available for analyst ratings or price target changes.
